MedImmune has received a $90 million order from the U.S. government for a live attenuated vaccine that can be used against the H1N1 outbreak. The vaccine developer says this could be the first of many new orders for a swine flu jab. And the company, the biotech arm of AstraZeneca, says it will begin shipping the first of 10 million doses of its seasonal flu vaccine in August. Report